New consortium aims to accelerate development of stem cell-based therapies for Huntington’s disease

NewsGuard 100/100 Score

The Stem Cells for Huntington's Disease (SC4HD) is a new international consortium created to promote advanced therapy medicinal product (ATMP) through cell transplantation studies on Huntington's Disease. The entity, made up of twenty-eight renowned researchers from ten countries, has been officially presented in a recent publication in the Journal of Huntington's Disease.

The main goals of SC4HD researchers are to work together with the HD community, develop criteria and guidance and address the main challenges to rapidly and safely bring potentially beneficial stem cell-based therapies to patients with this devastating disease.

According to Josep M. Canals, director of Creatio and member of the steering committee of SC4HD, "there is an exciting opportunity to apply stem cell-based therapies in Huntington's disease (HD), a devastating neurodegenerative disease that mainly affects neurons in the brain nucleus known as striatum".

To date, most experimental cell therapies have focused on the striatum aiming to replace the lost striatal neurons during the disease process. Therefore, this aims to repair the neuronal circuit and increase the survival of the remaining neuronal and glial striatal cells. Technological advances aimed to direct the differentiation of stem cells to desired neural types have opened new strategies for restoring damaged neuronal circuits in Huntington's.

The SC4H consortium brings together experts in stem cell biology, cell transplantation, clinical grade cell production, neurosurgery, and clinical evaluation. Its aim is to accelerate the safe clinical translation of stem cell therapy and to provide a comprehensive standardization and guidance for the field, spanning the full range of therapeutic considerations.

University of Barcelona participation

Josep M. Canals is a tenured university lecturer at the Department of Biomedical Sciences of the Faculty of Medicine and Health Sciences of the UB, and director of the Production and Validation Center for Advanced Therapies (Creatio), a TECNIO center for the production of Advanced Therapy Medicinal Products (ATMPs) in Catalonia. Also, he leads the Stem Cell and Regenerative research group of the UB.

Unai Perpiña, qualified person at Creatio and lecturer at the Department of Biomedicine, also participates in SC4HD.

Both researchers are members of the Institute of Neurosciences of the UB (UBNeuro), the Biomedical Research Networking Center on Neurodegenerative Diseases (CIBERNED), the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and the Spanish Network of Cell Therapy (Tercel).

Journal reference:

The SC4HD Consortium (2021) Stem Cells for Huntington’s Disease (SC4HD): An International Consortium to Facilitate Stem Cell-Based Therapy for Huntington’s Disease. Journal of Huntington's Disease.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel therapeutic approach identified for overcoming resistance in B-cell leukemia